. 2023 Feb 14;15(2):643. doi: 10.3390/pharmaceutics15020643

Table 6.

The secondary outcome measure based on SF-12 HRQoL.

Domains SF-12 HRQoL	Period	Pessary Group (n = 33)	Standard Group (n = 33)	p-Value
Total score	Day 0	50.89 ± 23.38	49.38 ± 26.85	0.808
	Day 14	94.25 ± 5.80 ^a	86.81 ± 13.14 ^b	0.004
	Day 30	95.50 ± 6.86 ^a	92.43 ± 11.88 ^b	0.203
Physical function (PF)	Day 0	37.88 ± 35.42	40.15 ± 33.62	0.79
	Day 14	87.12 ± 19.64 ^a	79.55 ± 19.22 ^b	0.118
	Day 30	90.53 ± 18.50 ^a	90.15 ± 18.69 ^b	0.934
Role limitation due to Physical Problems (RF)	Day 0	57.58 ± 25.38	66.67 ± 27	0.164
	Day 14	98.48 ± 8.70 ^a	100.00 ± 0.00 ^b	0.321
	Day 30	98.48 ± 8.70 ^a	100.00 ± 0.00 ^b	0.321
Role limitation due to Emotional Problems (RE)	Day 0	54.55 ± 38.25	56.06 ± 39.05	0.874
	Day 14	100.00 ± 0.00 ^a	96.97 ± 17.41 ^b	0.321
	Day 30	100.00 ± 0.00 ^a	96.97 ± 17.41 ^b	0.321
Energy/Fatigue/Vitality (VT)	Day 0	41.21 ± 29.97	37.27 ± 33.66	0.617
	Day 14	90.30 ± 11.32 ^a	82.73 ± 18.59 ^b	0.05
	Day 30	92.73 ± 10.98 ^a	83.64 ± 21.91 ^b	0.037
Emotional well-being Mental Health (MH)	Day 0	50.61 ± 30.1	51.52 ± 32.32	0.906
	Day 14	93.94 ± 9.33 ^a	90.00 ± 12.25 ^b	0.147
	Day30	96.06 ± 8.99 ^a	92.12 ± 12.19 ^b	0.14
Social Functioning (SF)	Day 0	63.70 ± 33.69	61.21 ± 38.39	0.781
	Day 14	96.36 ± 12.45 ^a	94.55 ± 9.05 ^b	0.5
	Day 30	96.36 ± 12.45 ^a	96.97 ± 7.28 ^b	0.81
Bodily Pain (BP)	Day 0	61.59 ± 26.07	52.27 ± 28.89	0.174
	Day 14	98.11 ± 10.88 ^a	87.12 ± 17.81 ^b	0.004
	Day 30	98.11 ± 10.88 ^a	94.69 ± 12.1 ^b	0.39
General Health (GH)	Day 0	13.26 ± 16.52	16.67 ± 20.41	0.459
	Day 14	79.92 ± 18.73 ^a	70.45 ± 19.22 ^b	0.047
	Day30	92.05 ± 18.70 ^a	83.33 ± 20.41 ^b	0.075

Paired and Unpaired ‘t’ Test; ^a p < 0.001 and ^b p < 0.001 on day 14 and day 30 from day 0 in the pessary and standard groups, respectively.